AbbVie Presents Five-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia at EHA 2022
- The P-III (CLL14) trial evaluates the combined regimen of Venclyxto/Venclexta + obinutuzumab vs obinutuzumab & chlorambucil in 432 patients with prior untreated CLL
- Results: @ median follow-up of 65.4mos., PFS remained significantly superior (median NR vs 36.4mos.), PFS rate (62.6% vs 27.0%) after 1yr. fixed-duration treatment, improvement in PFS across all risk groups, including patients with TP53 mutation/deletion & unmutated IGHV status, OS rate (81.9% vs 77.0) at 5yr. after randomization
- Additionally, patients still had uMRD (18.1% vs 1.9%) @ 4yrs. after treatment completion, no new safety signals were observed. The therapy is being developed by AbbVie & Roche & is jointly commercialized by AbbVie & Genentech
Ref: PRNewswire | Image: AbbVie
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.